Imperial said OCT is a biopharmaceutical company that researches, develops and licenses cannabinoid-based therapies and compounds. OCT is licensed for operation by the UK Home Office, Imperial said.
Matthew Phillips, chief development officer at Imperial Brands, said, “Cannabinoid products have significant potential and our investment enables Imperial to support OCT’s important research while building a deeper understanding of the medical cannabis market.”
|
